Clinical feasibility of oral low-dose etoposide and sobuzoxane for conventional chemotherapy–intolerant lymphoma patients-Reference-Cited by-同舟云学术

Clinical feasibility of oral low-dose etoposide and sobuzoxane for conventional chemotherapy–intolerant lymphoma patients

Published:2021-03-09 Issue:7 Volume:21 Page:715-722
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Ohmoto Akihiro¹^ORCID,Fuji Shigeo²

Affiliation:

1. Division of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

2. Department of Hematology, Osaka International Cancer Institute, Osaka, Japan

Funder

funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2021.1898376

Reference46 articles.

1. Older adults in hematologic malignancy trials: Representation, barriers to participation and strategies for addressing underrepresentation

2. Etoposide: four decades of development of a topoisomerase II inhibitor

3. NCCN clinical practice guidelines in oncology. T-cell lymphomas (version 1, 2020). [Cited 2020 Aug 11]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf

4. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.

5. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Studying the DNA damage response pathway in hematopoietic canine cancer cell lines, a necessary step for finding targets to generate new therapies to treat cancer in dogs;Frontiers in Veterinary Science;2023-08-16